Navigation Links
FDA Proposes Tighter Regulation of Public Defibrillators
Date:3/23/2013

By Steven Reinberg
HealthDay Reporter

FRIDAY, March 22 (HealthDay News) -- To improve the quality of lifesaving devices called automated external defibrillators, the U.S. Food and Drug Administration proposed Friday that the seven manufacturers of these devices be required to get agency approval for their products.

Automated external defibrillators (AEDs) are portable devices that deliver an electrical shock to the heart to try to restore normal heart rhythms during cardiac arrest. Although the FDA is not recalling AEDs, the agency said that it is concerned with the number of recalls and quality problems associated with them.

"[The] FDA is not questioning the clinical utility of AEDs," Dr. William Maisel, chief scientist in FDA's Center for Devices and Radiological Health, said during a press conference on Friday announcing the proposal.

"These devices are critically important and serve a very important public health need. The importance of early defibrillation for patients who are suffering from cardiac arrest is well-established," he said.

Maisel added the FDA is not calling into question the safety or quality of AEDs currently in place around the country.

There are about 2.4 million such devices in public places throughout the United States, according to The New York Times.

"Today's action does not require the removal or replacement of AEDs that are in distribution. Patients and the public should have confidence in these devices, and we encourage people to use them under the appropriate circumstances," Maisel said.

Although there have been problems with AEDs, their lifesaving benefits outweigh the risk of making them unavailable, Maisel explained.

Dr. Moshe Gunsburg, director of cardiac arrhythmia service and co-chief of the division of cardiology at Brookdale University Hospital and Medical Center in Brooklyn, N.Y., supports the FDA proposal.

"Cardiac arrest is the leading cause of death in the United States. It claims over 250,000 lives a year," he said.

Early defibrillation is the key to helping patients survive, Gunsburg said. Timing, however, is critical. If a patient is not defibrillated within four to six minutes, brain damage starts and the odds of survival diminish with each passing minute, which is why 90 percent of these patients don't survive, he explained.

The best chance a patient has is an automated external defibrillator used quickly, which is why Gunsburg and others want AEDs to be as common as fire extinguishers so laypeople can use them when they see someone go into cardiac arrest. The FDA's action will help ensure that these devices are in top shape when they are needed, he said.

But, there have been problems and failures with AEDs. Between 2005 and 2012 the FDA received about 45,000 reports of failure of these devices. In addition, there have been 88 recalls, Maisel said.

According to Maisel, it isn't known whether failures of AEDs cause any deaths. That's because when these devices are used, patients are in cardiac arrest and most die even when an AED is used and works well, he said.

However, machine defects may have contributed to patient deaths, the Times reported. For example, in one case, a nurse was attempting to attach a patient in cardiac arrest to a defibrillator when the device's screen read "memory full." In another case, a problem with a defibrillator's software caused the device to read "equipment disabled" as it was being used on a patient. In both cases, the patient died, the newspaper said.

The actual number of AED failures is also not known, but, "it's quite small," Maisel said. The most common problems are random power shutdowns, erroneous error messages and failure of the components of the machine, he noted.

"Tens of thousands of adverse events is too many. We think 88 recalls are too many," Maisel said.

"So, by calling for pre-market approval we can focus our attention on the types of problems that have been observed and our expectation is that we will observe an improvement in the reliability over time with these devices," he said.

This action is being taken based on the recommendation of the FDA's Circulatory System Devices Panel, which wants AEDs to be a Class III medical device requiring pre-market approval.

AEDs were on the market before the current approval process for Class III medical devices was updated, so they didn't need pre-market approval. But given their problems they should now require approval, Maisel said.

In addition to the safety and effectiveness data, the application must include a review of a manufacturer's quality systems and an inspection of its plant.

According to the FDA, after the device is approved, the manufacturer must submit any significant changes made to the device, as well as a yearly report on the device's performance.

The public will have 90 days to comment on the FDA proposal. When the proposal becomes final, the process of getting all AEDs approved will take about two years, Maisel said.

More information

For more information on automated external defibrillators, visit the U.S. National Heart, Lung, and Blood Institute.

SOURCES: Moshe Gunsburg, M.D., director, cardiac arrhythmia service, co-chief, division of cardiology, Brookdale University Hospital and Medical Center, Brooklyn, N.Y.; March 22, 2013, press conference with William Maisel, M.D., M.P.H., deputy director of science and chief scientist, Center for Devices and Radiological Health, U.S. Food and Drug Administration; The New York Times


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Proposes New Rules to Strengthen Food Safety
2. EPA Proposes New Cuts on Levels of Soot in Air
3. IADR/AADR publish studies on severe early childhood caries - proposes new classification
4. Nouvelle Research, Inc. studies show chronic inflammation reduction through NRF2 Upregulation and NF-kB Downregulation, Cur-OST® Supplements Positively Impact Health
5. GW researcher receives federal grant to study hedgehog regulation of cell-cell interaction
6. American Emu Association Updates Quality Regulations in Response to Fraudulent Oils in Market
7. Abnormal growth regulation may occur in children with heart defects
8. Growing medicines in plants requires new regulations
9. FDA, States Weigh Pharmacy Regulation in Wake of Meningitis Outbreak
10. I Fly First Class Announces Very Important New Tips and Regulation For Travelers
11. Dec. 12 Atlantic Information Services Webinar to Address the Nuances of New HHS Essential Health Benefits Regulations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... For ... assistance management solution to the exhibit floor for the 2017 HIMSS Conference ... , From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... ... 2017 , ... Pharmica Consulting attended CHI's 8th Annual SCOPE ... trial planning and management. Pharmica discussed the importance of effective project management, data ... by Pharmica’s booth were able to demo its cloud-based Resource Management Tool, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from ... February 21 - 23 in Beaver Creek, CO. It was announced today by Cindy ... year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs of ...
(Date:2/16/2017)... ... 17, 2017 , ... For some cancer survivors, the memories ... Physician researchers at The Marcus Institute of Integrative Health at Thomas Jefferson ... reducing symptoms of traumatic stress in cancer patients and published their results ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 17, 2017  Noble Capital Markets announced today that ... (Nasdaq: EPIX ). The report was issued ... , PhD. ESSA Pharmaceuticals is a clinical ... cancer (CRPC). Its lead compound EPI-506, is a small ... of the androgen receptor, thereby has potential to overcome ...
(Date:2/16/2017)... Quest Diagnostics (NYSE: DGX ), ... announced that it has been named one of the ... The annual survey designated Quest Diagnostics as ... Pharmacy and Other Services" industry to attain Most Admired ... attain the designation. This is the second consecutive year ...
(Date:2/16/2017)... Feb. 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... company, today announced that executive management will participate in ... held February 22-23, 2017. Adrian Adams , Chief ... at 1:35 p.m. local time on Wednesday, February 22, ... for the event may be accessed from the Investors ...
Breaking Medicine Technology: